MBX Biosciences, Inc.
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.79M | 6.34M | 4.66M | 4.08M | 4.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.27M | 25.80M | 23.93M | 21.81M | 26.53M |
| Operating Income | -27.27M | -25.80M | -23.93M | -21.81M | -26.53M |
| Income Before Tax | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M |
| EBIT | -27.27M | -25.80M | -23.93M | -21.81M | -26.53M |
| EBITDA | -27.20M | -25.74M | -23.88M | -21.74M | -26.45M |
| EPS Basic | -0.50 | -0.49 | -0.63 | -0.58 | -0.71 |
| Normalized Basic EPS | -0.32 | -0.36 | -0.40 | -0.36 | -0.47 |
| EPS Diluted | -0.50 | -0.49 | -0.63 | -0.58 | -0.71 |
| Normalized Diluted EPS | -0.32 | -0.36 | -0.40 | -0.36 | -0.47 |
| Average Basic Shares Outstanding | 46.58M | 44.87M | 34.20M | 33.45M | 33.41M |
| Average Diluted Shares Outstanding | 46.58M | 44.87M | 34.20M | 33.45M | 33.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |